Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

Inclusion Criteria:

- must have metastatic breast cancer

- must have cytologically or pathologically confirmed invasive ductal or lobular
carcinoma

- must have measurable or evaluable disease

- ECOG of 0-1

- patients may have received 0, 1. or 2 prior treatments for metastatic breast cancer

- must have adequate organ function

- must be at least 19 years of age

- peripheral neuropathy less than or equal to grade 1

- must have voluntarily signed informed consent

- patients with brain metastases are eligible provided that other measurable disease
exists and brain lesions are controlled

Exclusion Criteria:

- patients with other malignancies, except non melanoma of the skin, who have had any
evidence of cancer within the last 5 years

- patients with psychiatric illness or other concurrent severe co-morbid medical
condition that would preclude study completion

- known uncontrolled existing coagulopathy

- patients with a history of severe hypersensitivity reaction to docetaxel, medications
formulated with polysorbate 80 or 5-fluorouracil

- use of other investigational agents in the last 28 days

- pregnant or lactating women

- patients who are known HIV positive

- patients with life expectancy of less than 3 months

- sexually active patients unwilling to practice reliable contraception during the
study